The adequacy of GlaxoSmithKline PLC’s Breo Ellipta safety database, particularly whether a large safety trial is needed to evaluate serious asthma outcomes, will be the focus of an FDA advisory committee’s March 19 review of a new asthma indication.
At a joint meeting, FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees will also review the efficacy...